#ES­MO22: Trodelvy's long-await­ed sur­vival da­ta in breast can­cer are fi­nal­ly in — and bet­ter than ex­pect­ed

It’s been weeks since Gilead tout­ed “clin­i­cal­ly mean­ing­ful” over­all sur­vival re­sults from a sec­ond in­ter­im analy­sis of Trodelvy in a sub­set of metasta­t­ic breast can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER